Metabolic Syndrome
Conditions
Keywords
Metformin, Agave Inulin, METS, Inflammation parameters, Urodynamic parameters, Prostate hyperplasia
Brief summary
Type 2 diabetes mellitus, insulin resistance, visceral obesity and disorders of lipid metabolism, especially triglyceride and hypertension are metabolic disorders that play a central role in pathophysiology of metabolic syndrome, and ultimately, the cardiovascular morbidity and mortality associated with atherosclerosis, such as myocardial infarction, cerebral vascular events, vascular dementia, heart failure and end stage renal disease. Recently other complications related with hyperinsulinemia like the prostate benign hypertrophy (BPH). Metformin is the treatment of choice in patients with metabolic syndrome, given its low cost and comparable pharmacological effects to the tiazolinedionas (eg pioglitazone), decreasing hyperinsulinemia, insulin resistance, concentration of free fatty acids and triglycerides, also it produces moderate weight loss, improving the metabolic profile triglcerides atherogenic lipid and carbohydrate and delaying the onset of diabetes mellitus in individuals with impaired fasting glucose. A second option for risk reduction would be the addition of inulin fiber type as it has been demonstrated some metabolic effects on benefices lipid metabolism and carbohydrate. It is expected that combination of metformin with inulin produce a beneficial effect through farmacological synergism and the impact on fisiopatological changes of metabolic syndrome that potentially is considered as an important risk factor for prostate growth.
Detailed description
The main objective is to evaluate the effect of the combination of metformin / inulin on clinical, urodynamic parameters as well as metabolic and inflammatory profile in patients with benign prostate hypertrophy and metabolic syndrome. The investigators conducted a double-blind trial, randomized, on 4 groups, each group with 15 male and female patients of 40 to 80 years of age with METS diagnosed by IDF criteria and clinical diagnose of HBP. Randomization will determine who will receive the intervention during 12 week trial, each group will be like: Group (A) intervention with combination metformin/ inulin: 15 individuals recieved combination of metformin/ agave inulin in a dosis of 500 mg / 10 grs per 24hrs during 12 weeks. Group (B) Metformin plus Placebo of agave inulin: 15 individuals recieved Metformin in a dosis of 500mg per day (with the first bite of the second meal) plus homologue placebo of agave inulin (calcinated magnesia) in a dosis of 10grs each 24 hrs during 12 weeks. Group (C) agave inulin plus placebo of Metformin: 15 indivuduals recieved agave inulin in a dosis of 10grs per 24hrs plus homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 12 weeks. Group (D) Placebo of agave inulin plus Placebo of Metformin: homologate placebo of agave inulin (calcinated magnesia) in a dosis of 10 grs each 24 hrs plus homologate placebo of metformin (calcinated magnesia capsules) in a dosis of 500 mg per day (with the first bite of the second meal) during 12 weeks. The clinical findings and laboratory test include a metabolic profile and biosafety, will be baseline and at 12 weeks. Clinical components of Mets like antropometrics parameters, fasting glucose, fasting insulin, blood lipids, clinical finding of HBP and inflammation parameters and adipocitocins, IGF-1, insulin, prostatic specific antigen. Adverse events and adherence to treatment will be documented. Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. It is considered with significance at p\<0.05.
Interventions
DRUGMetformin
Metfomin in tablet presentation of 500 mg
DIETARY_SUPPLEMENTAgave inulin
Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
Calcinated magnesia powder
OTHERMetformin placebo
Calcinated magnesia tablet
Sponsors
Centro Universitario de Ciencias de la Salud, Mexico
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of metabolic syndrome by IDF criteria * a person to be defined as having the metabolic syndrome they must have: Central obesity (defined as waist circumference\* with ethnicity specific values) ≥80 cm in females and ≥90 cm in males; and plus any two of the following four factors: * Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality Reduced HDL cholesterol * \< 40 mg/dL (1.03 mmol/L) in males \< 50 mg/dL (1.29 mmol/L) in females or specific treatment for this lipid abnormality * Raised blood pressure systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension * Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes * Age ranging from 40 to 80 years old * Male patients * Informed written consent
Exclusion criteria
* Kidney disease * Hepatic disease * Thyroid disease * Diabetes mellitus * Ischemic heart disease * Drug consumption * Alcohol consumption of more than 2 ounces daily * Consumption of drugs that intervene with lipid or glucose metabolism 2 months before * Blood pressure \>160/100mmHg. * Lack of adherence to treatment (adherence \<80%)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| International Prostate Symptom Score (I-PSS) | 12 weeks | before and after intervention questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Fasting plasma glucose at 12 weeks | 12 weeks | Before and after intervention by glucose oxidase |
| Change of waist circumference | 12 weeks | Measured with a non elastic tape at baseline and after intervention |
| Change of body mass index | 12 weeks | before and after intervention using a tetrapolar bioelectrical impedance analyzer (body composition analyzer TBF-215 - Tanita) |
| Change from baseline in Peripheral systolic blood pressure | 12 weeks | Before and after intervention using a digital sphygmomanometer |
| Change from baseline in Peripheral diastolic blood pressure | 12 weeks | Before and after intervention using a digital sphygmomanometer |
| Change from Baseline in Total cholesterol at 12 weeks | 12 weeks | Before and after intervention by spectrophotometry |
| Change from baseline in High-density lipoprotein cholesterol at 12 weeks | 12 weeks | Before and after intervention by spectrophotometry |
| Change from Baseline in Triglycerides at 12 weeks | 12 weeks | Before and after intervention by spectrophotometry |
| qmax urine flow rate | 12 weeks | before and after intervention by uroflowmetry |
| prostate serum antigen | 12 weeks | before and after intervention by colorimetry |
| Change of HOMA-IR from base line to 12 weeks | 12 weeks | Before and after intervention by using the formula for the homeostasis model assessment β-cell function index: 20 x fasting insulin (µU/Ml)/fasting glucose (mmol/L) - 3.5. |
Countries
Mexico
Outcome results
None listed